多中心比较研究表明，与常用疗法相比，服用一片 85 毫克舒马曲坦和 500 毫克萘普生可更有效地治疗多次偏头痛发作，这可通过应答完全性调查来衡量。
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey.
机构信息
Headache Care Center, Springfield, MO, USA.
出版信息
Headache. 2011 Jun;51(6):961-70. doi: 10.1111/j.1526-4610.2011.01912.x. Epub 2011 May 17.
OBJECTIVE
To investigate a broad definition of migraine resolution that extends beyond specific migraine-associated diagnostic symptoms as measured by the Completeness of Response Survey.
METHODS
Conducted at 8 sites, 135 subjects treated migraines with SumaRT/Nap over 2 months. To measure subjects' experiences with SumaRT/Nap compared to their usual migraine medication, the Headache Impact Test, Revised Patient Perception of Migraine Questionnaire, and Completeness of Response Survey were administered at baseline and at 2 months.
RESULTS
The effects of the study medicine compared to the subjects' usual migraine medicine reached statistical significance in decreasing headache severity, lessening of associated symptoms, and attaining complete relief with a single dose (60.04% of attacks resolved at 2 hours post-treatment).
CONCLUSION
Compared to a subject's usual treatment, SumaRT/Nap used early and consistently for treatment of acute migraine offers important clinical improvements, including lessening of associated symptoms beyond International Headache Society criteria.
CLINICAL TRIAL REGISTRATION NUMBER
NCT00893737.
目的
通过反应完全度调查，对偏头痛缓解进行广义定义的研究，该定义超越了特定的偏头痛相关诊断症状。
方法
在 8 个地点进行，135 名偏头痛患者接受 SumaRT/Nap 治疗，为期 2 个月。为了测量与患者的常用偏头痛药物相比，SumaRT/Nap 的使用体验，在基线和 2 个月时使用头痛影响测试、修订偏头痛患者感知问卷和反应完全度调查进行评估。
结果
与患者的常用偏头痛药物相比，研究药物在降低头痛严重程度、减轻相关症状和单次剂量即可获得完全缓解方面具有统计学意义（60.04%的发作在治疗后 2 小时内得到缓解）。
结论
与患者的常用治疗相比，早期且持续使用 SumaRT/Nap 治疗急性偏头痛可带来重要的临床改善，包括减轻与国际头痛协会标准相关的症状。
临床试验注册号
NCT00893737。
Zotero 插件